Fluidigm Corporation reported a decrease in first quarter revenue of 8 percent, totaling $27.6 million, down from $30.1 million. The company experienced a GAAP net loss of $16 million, an improvement from a loss of $25.5 million a year prior. Key growth opportunities arose in the context of COVID-19, with customers seeking FDA Emergency Use Authorization for ultrahigh-throughput tests. Fluidigm is adapting to market changes by repositioning its products and managing operating expenses amid the pandemic.
Fluidigm Corporation (Nasdaq: FLDM) has launched its new Therapeutic Insights Services, providing mass cytometry and Imaging Mass Cytometry (IMC) services to researchers. This initiative aims to facilitate research by offering consultation, custom antibody sourcing, and data analysis tools. The services are particularly beneficial for customers affected by COVID-19 laboratory closures. In collaboration with Visikol, Fluidigm enhances access to IMC technology, allowing for rich data acquisition and analysis. The launch responds to the urgent need for advanced imaging tools in studying disease progression and therapeutic responses.